Technojet Consultants Limited has announced the divestment of its equity stake in INOR Medical Products Limited through a regulatory filing dated 25th February, 2026. The transaction represents a strategic portfolio adjustment by the company as it exits its investment in the unlisted medical products manufacturer.

Transaction Details

The divestment involves the complete sale of Technojet Consultants Limited's holding in INOR Medical Products Limited. The company has disclosed the transaction details in compliance with regulatory requirements.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions.

The disclosure was signed by Bhumika Ojha, Company Secretary (Membership No.: A79488), ensuring proper corporate governance protocols were followed. The digital signature was applied on 25th February, 2026, at 16:41:04 +05'30', confirming the authenticity of the regulatory filing.

Corporate Background

Technojet Consultants Limited operates under CIN L74210MH1982PLC027651 and maintains its listing on BSE Limited with scrip code 509917. The company's decision to divest from INOR Medical Products Limited reflects its ongoing portfolio management strategy, though specific financial details of the transaction were not disclosed in the regulatory filing.

Oseaspre consultants Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results at their meeting held on February 12, 2026, marking another challenging period for the consulting firm.

Financial Performance Overview

The company reported a net loss of ₹3.90 lakh for the third quarter of FY26, representing a marginal increase from the ₹3.83 lakh loss recorded in the corresponding quarter of the previous fiscal year. The nine-month performance showed a widening of losses, with the company posting a net loss of ₹11.80 lakh compared to ₹10.27 lakh in the same period of FY25.

Revenue and Income Analysis

Oseaspre Consultants Limited continues to operate without any revenue from operations during the quarter. The company's total income for Q3FY26 was limited to other income of ₹0.55 lakh, which declined from ₹0.95 lakh in Q3FY25. For the nine-month period, other income totaled ₹1.93 lakh compared to ₹3.25 lakh in the previous year.

Expense Structure

Total expenses for the third quarter stood at ₹4.45 lakh, slightly lower than ₹4.78 lakh in Q3FY25. The expense breakdown reveals:

For the nine-month period, total expenses increased to ₹13.73 lakh from ₹13.52 lakh in the corresponding period of FY25, with employee benefits expense rising to ₹7.43 lakh from ₹7.09 lakh.

Earnings Per Share and Capital Structure

The company's basic and diluted earnings per share for Q3FY26 stood at ₹(1.95) compared to ₹(1.92) in Q3FY25. The nine-month EPS deteriorated to ₹(5.90) from ₹(5.14) in the previous year. The paid-up share capital remained unchanged at ₹20.00 lakh, consisting of 200,000 equity shares of ₹10 each.

Regulatory Compliance and Auditor Review

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by Manek & Associates, Chartered Accountants. The results were subject to limited review by the statutory auditors, who expressed no material concerns regarding the financial statements. The company noted that it has no reportable segments as per Ind AS 108 due to the absence of revenue from operations.